Sector revisions Akeso, Inc.

Equities

Market Closed - Hong Kong S.E. Other stock markets 01:38:03 11/07/2025 pm IST			5-day change	1st Jan Change
113.20 ^HKD	+4.52%		+6.69%	+86.49%

03/07	Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports	RE
03/07	Akeso's First Bispecific Adc (Trop2/Nectin4 Adc) Enters Clinical Trials, Strengthening Leadership in 'Io+Adc'2.0 Strategy	CI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility (Composite)	Nbr of analysts
	AKESO, INC.							20
	ARGENX SE							16
	BIONTECH SE							21
	WUXI APPTEC CO., LTD.							18
	SUMMIT THERAPEUTICS INC.							9
	INSMED INCORPORATED							18
	GENMAB A/S							16
	WUXI BIOLOGICS (CAYMAN) INC.							26
	EXELIXIS, INC.							19
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.							16
	VERONA PHARMA PLC							9
	LEGEND BIOTECH CORPORATION							20
	MADRIGAL PHARMACEUTICALS, INC.							14
	PHARMAESSENTIA CORPORATION							4
	SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.							2
	NUVALENT, INC.							10
	BIOCON LIMITED							20
	REMEGEN CO., LTD.							15
	VAXCYTE, INC.							8
	Average							15
	Weighted average by Cap.							16